The National Institutes of Health has appointed Mark Guyer to deputy director of the National Human Genome Research Institute and James Mullikin to director of the NIH Intramural Sequencing Center.
Guyer is currently the director of NHGRI's Division of Extramural Research, and has been at the NHGRI for the last 23 years where he has participated in a number of NHGRI activities including genome sequencing and the creation of the Ethical, Legal and Social Implications program. In his new role he will help implement the institute's new strategic plan (IS 2/15/2011). Guyer holds a PhD in bacteriology and immunology from the University of California, Berkeley.
James Mullikin has been the acting director of the NIH Intramural Sequencing Center since 2003, and will now become the permanent director. He is also an associate investigator in NHGRI's genome technology branch and head of the comparative genomics unit. As director of NISC, he will continue to apply genome sequencing technologies to clinical research, especially with its largest project, ClinSeq. Prior to joining the NHGRI, Mullikin led the production informatics department at the Wellcome Trust Sanger Institute. He holds a PhD in physics from Delft University of Technology in Delft, The Netherlands, and a BS and MS in electrical engineering from Purdue University.
Ramesh Ramanathan is now the chairman of the executive board of the international Pancreatic Cancer Research Team, a network of clinical trial sites organized under TGen Drug Development, a subsidiary of the Translational Genomics Research Institute. Ramanathan is a clinical professor and deputy director of TGen's clinical translational research division and medical director of Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare.
The Garvan Institute of Medical Research in Sydney, Australia, has appointed John Mattick as its next executive director, following the retirement of John Shine in January 2012. Mattick will join the Garvan Institute from the University of Queensland where he is a professor in the Institute of Molecular Bioscience. His research has focused on using targeted deep sequencing to characterize regulatory RNAs, including their functions in both normal development and disease states. In his new position, he will focus on tying together high-throughput sequencing and molecular approaches to studying diseases such as cancer and diabetes. He holds a BS from the University of Sydney and a PhD from Monash University in Melbourne.
The University of British Columbia has appointed Matthew Farrer to be the Donald Rix BC Leadership Chair in Genetic Medicine.
Farrer was appointed as the Canada Excellence Research Chair of Neurogenetics and Translational Neuroscience at UBC in 2010, and he was a professor of molecular neuroscience and director of the Mayo Clinic's Neurogenetics Division. His current research interests focus on neurodegenerative disorders, such as the molecular genetics and functional modeling of movement disorders, including Parkinson's disease and Lewy body dementia.
He holds a BS in biochemistry from King's College London and a PhD in human genetics from Imperial College London.